Literature DB >> 20959851

Platelet mitochondrial complex I and I+III activities do not correlate with cerebral mitochondrial oxidative metabolism.

William J Powers1, Richard H Haas, Thuy Le, Tom O Videen, Joanne Markham, Joel S Perlmutter.   

Abstract

Assays of mitochondrial electron transport system (ETS) activity in circulating blood platelets have been used to investigate the cause of neurodegenerative diseases. However, the correspondence between platelet ETS function and cerebral mitochondrial metabolism is not well characterized. To assess the validity of using platelet ETS activity to infer cerebral mitochondrial metabolism, we measured platelet ETS activity (complex I and complex I+III), cerebral metabolic rate of oxygen (CMRO(2)), and the CMRO(2)/cerebral metabolic rate for glucose ratio in 40 subjects: 7 with never-medicated Parkinson's disease, 13 with genetically proved Huntington's disease, and 20 normal controls. We found no correlation between in vivo measures of cerebral mitochondrial oxidative metabolism and ex vivo assays of platelet complex I and complex I+III activity performed on blood collected immediately before cerebral metabolism studies. We saw no evidence of a threshold effect when comparing platelet complex I and complex I+III activity with cerebral oxidative metabolism across a 4- to 10-fold range of platelet ETS activity. On the basis of these data, we conclude that measures of mitochondrial complex I and I+III activity in platelets within the ranges we have studied do not correlate with oxidative function of cerebral mitochondria.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20959851      PMCID: PMC3049467          DOI: 10.1038/jcbfm.2010.179

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  26 in total

1.  [THE CARBOHYDRATE METABOLISM OF THE HUMAN BRAIN. I. STUDIES WITH SUBSTRATE-SPECIFIC ENZYMATIC METHODS IN NORMAL BRAIN CIRCULATION].

Authors:  U GOTTSTEIN; A BERNSMEIER; I SEDLMEYER
Journal:  Klin Wochenschr       Date:  1963-10-01

2.  Correction for partial volume effects in regional blood flow measurements adjacent to hematomas in humans with intracerebral hemorrhage: implementation and validation.

Authors:  T O Videen; J E Dunford-Shore; M N Diringer; W J Powers
Journal:  J Comput Assist Tomogr       Date:  1999 Mar-Apr       Impact factor: 1.826

3.  MRI-PET registration with automated algorithm.

Authors:  R P Woods; J C Mazziotta; S R Cherry
Journal:  J Comput Assist Tomogr       Date:  1993 Jul-Aug       Impact factor: 1.826

4.  Quantitative study of mitochondrial complex I in platelets of parkinsonian patients.

Authors:  F Blandini; G Nappi; J T Greenamyre
Journal:  Mov Disord       Date:  1998-01       Impact factor: 10.338

5.  Platelet mitochondrial respiratory chain function in Parkinson's disease.

Authors:  C I Blake; E Spitz; M Leehey; B J Hoffer; S J Boyson
Journal:  Mov Disord       Date:  1997-01       Impact factor: 10.338

6.  Selective defect of in vivo glycolysis in early Huntington's disease striatum.

Authors:  William J Powers; Tom O Videen; Joanne Markham; Lori McGee-Minnich; Joann V Antenor-Dorsey; Tamara Hershey; Joel S Perlmutter
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-13       Impact factor: 11.205

7.  Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects.

Authors:  C W Shults; R H Haas; D Passov; M F Beal
Journal:  Ann Neurol       Date:  1997-08       Impact factor: 10.422

8.  Glucose metabolism in human malignant gliomas measured quantitatively with PET, 1-[C-11]glucose and FDG: analysis of the FDG lumped constant.

Authors:  A M Spence; M Muzi; M M Graham; F O'Sullivan; K A Krohn; J M Link; T K Lewellen; B Lewellen; S D Freeman; M S Berger; G A Ojemann
Journal:  J Nucl Med       Date:  1998-03       Impact factor: 10.057

9.  Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease.

Authors:  R H Haas; F Nasirian; K Nakano; D Ward; M Pay; R Hill; C W Shults
Journal:  Ann Neurol       Date:  1995-06       Impact factor: 10.422

10.  Normal platelet mitochondrial complex I activity in Huntington's disease.

Authors:  William J Powers; Richard H Haas; Thuy Le; Tom O Videen; Tamara Hershey; Lori McGee-Minnich; Joel S Perlmutter
Journal:  Neurobiol Dis       Date:  2007-05-05       Impact factor: 5.996

View more
  5 in total

Review 1.  The chicken or the egg: mitochondrial dysfunction as a cause or consequence of toxicity in Huntington's disease.

Authors:  Aris A Polyzos; Cynthia T McMurray
Journal:  Mech Ageing Dev       Date:  2016-09-12       Impact factor: 5.432

Review 2.  Shaping the role of mitochondria in the pathogenesis of Huntington's disease.

Authors:  Veronica Costa; Luca Scorrano
Journal:  EMBO J       Date:  2012-03-23       Impact factor: 11.598

3.  Platelet mitochondrial activity and pesticide exposure in early Parkinson's disease.

Authors:  Jeff M Bronstein; Kimberly Paul; Laurice Yang; Richard H Haas; Clifford W Shults; Thuy Le; Beate Ritz
Journal:  Mov Disord       Date:  2015-03-11       Impact factor: 10.338

4.  Oxygen consumption deficit in Huntington disease mouse brain under metabolic stress.

Authors:  Song Lou; Victoria C Lepak; Lynn E Eberly; Brian Roth; Weina Cui; Xiao-Hong Zhu; Gülin Öz; Janet M Dubinsky
Journal:  Hum Mol Genet       Date:  2016-05-18       Impact factor: 6.150

5.  Platelet mitochondrial membrane potential in Parkinson's disease.

Authors:  Paul M A Antony; Olga Boyd; Christophe Trefois; Wim Ammerlaan; Marek Ostaszewski; Aidos S Baumuratov; Laura Longhino; Laurent Antunes; Werner Koopman; Rudi Balling; Nico J Diederich
Journal:  Ann Clin Transl Neurol       Date:  2014-12-11       Impact factor: 4.511

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.